In preclinical studies of lung cancer, two novel FAK-PROTACs (PROTAC-A13 and PROTAC B5) demonstrated superior FAK degradation compared with the FAK inhibitor PF-562271 (PROTAC-A13: 85% degradation at 10 nM; PROTAC-B5: 86.4% degradation at 10 nM), as well as potent anti-cancer activity (PROTAC-A13: IC50 value of 26.4 nM; PROTAC-B5: IC50 = 0.14 μM). Here, PTK2 is linked to cancer.